"Beyond efficacy, Enhertu has also been linked to a potentially dangerous side effect known as interstitial lung disease (ILD), which causes scarring of the lungs. In Destiny-Breast04, 45 Enhertu patients (12.1%) experienced drug-related interstitial lung disease, according to an independent review committee, including 3 (0.8%) deaths. By comparison, only 1 patient in the chemo arm experienced a low, grade 1 case of the lung problem."
https://www.fiercepharma.com/pharma/asco-astrazeneca-daiichis-enhertu-transform-breast-cancer-treatment-practice-changing-her2
Media Thread, page-5842
-
- There are more pages in this discussion • 8,823 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |